Pillar VC

Pillar VC is a Boston-based seed and early-stage firm that has built one of the most credible founder-first franchises in the New England technology and life sciences ecosystem. Founded in 2016 with a thesis grounded in ‘partnering from the beginning’ with technically brilliant founders, Pillar runs a generalist book that covers deep tech, biotech, health, AI, and frontier enterprise. The firm announced its $175 million Fund IV in March 2025, bringing total assets under management to more than $500 million across more than 150 portfolio companies. Pillar is unusual at seed for explicitly funding founder-led biotech, and the firm has staked out a distinctive position betting on technical founders rather than the traditional life sciences playbook of pharma-trained CEOs and serial venture executives.

Tony Kulesa, a Pillar partner since 2021, anchors the biotech and life sciences practice. With a background in Biomedical Engineering and a long track record across the Boston life sciences ecosystem, Kulesa has championed the thesis that the future of biotech is founder-led, and he has invested across companies including Thymmune (machine learning-driven thymic cell engineering), Vivere Oncotherapies (directed evolution for personalized cancer vectors), Skeletalis (bone health and women’s health platform), and Asimov (synthetic biology and cell programming). Other partners include Jamie Goldstein and Sarah Hodges on the broader Pillar team, with several venture and operating partners drawn from the Boston technical and clinical communities. The firm’s portfolio also includes Abridge, the AI-driven medical scribe and clinical documentation platform; PathAI, the digital pathology and AI-powered diagnostics company; VideaHealth, the FDA-cleared dental AI platform; and Reclaim, an AI-powered claims advocacy platform for employers.

Pillar writes initial seed checks of $250,000 to $5 million, with Fund IV providing the capacity for select Series A and follow-on positions up to $10 million. The firm leads or co-leads at seed and is comfortable being the first institutional check, frequently writing alongside angel investors, founder-friendly seed funds, and specialist healthcare and biotech investors at slightly later rounds. Geographic scope is heavily Boston-Cambridge centered, with selective deals across the broader US and rare exceptions internationally, particularly when the founder is connected to MIT, Harvard, or the broader Boston technical ecosystem.

Founders who should approach Pillar are technical founders, particularly PhD scientists and engineers who are first-time CEOs, building biotech, health AI, computational biology, or deep tech infrastructure. Pillar is one of the few seed firms that will write a $1 million to $3 million check to a postdoc or principal investigator with a translational program and help them recruit a co-founder, build a team, and assemble a Series A syndicate. Founders building consumer DTC brands, pure healthcare services without a deep tech wedge, or generic SaaS plays should pitch other firms. Founders looking for growth capital or Series B and beyond should look elsewhere; Pillar is decisively a seed and early Series A specialist.

Entry path runs through MIT, Harvard, and Broad Institute affiliations, portfolio CEOs, the Boston-Cambridge technical community, and warm introductions from peer seed funds. Kulesa and the partnership are publicly accessible at conferences including JPMorgan Healthcare, BIO, and Boston-area academic events. Pillar runs an editorial blog and podcast that signal current thesis priorities, and Kulesa in particular has been a public voice for the founder-led biotech thesis. Cold inbound is read and the firm has a more open posture toward direct outreach than many tier-one peers, particularly when the founder is academically credentialed.

In a pitch, lead with the science, the founder market fit, and the technical wedge. Pillar partners want to see a defensible scientific or engineering insight, a credible plan to build a team and translate the insight into a product or asset, and a founder who is genuinely capable of becoming a CEO. They will probe your IP estate, your technical roadmap, and your near-term experimental plan in detail. The firm’s added value is best realized when founders use Pillar’s deep Boston-Cambridge network for hiring, scientific advisors, syndicate building, and downstream Series A introductions to peer specialists including F-Prime, Third Rock, Versant, DCVC Bio, and Atlas Venture. Founders who want a true partner from formation, one who will support them through the messy early company-building work and prepare them for a credible Series A, will find Pillar one of the most useful tier-one seed firms in the Boston biotech and health AI ecosystem.